Purified NA/LE Mouse Anti-Human CD253
Clone RIK-2 (RUO)
- Brand BD Pharmingen™
- Alternative Name TNFSF10; TRAIL; APO-2L; TL2
- Concentration 1.0 mg/ml
- Isotype Mouse IgG1
- Reactivity Human (QC Testing)
Flow cytometry (Routinely Tested)
Blocking, Bioassay (Tested During Development)
- Immunogen Human TRAIL Transfected Cell Line
- Storage Buffer No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.
- Regulatory Status RUO
Regulatory Status Legend
The RIK-2 monoclonal antibody specifically binds to CD253, also known as TRAIL (TNF-Related Apoptosis-Inducing Ligand) and Apo2 ligand (APO-2L). CD253 is a member of the Tumor Necrosis Factor Superfamily and is encoded by the TNFSF10 gene. CD253 is a type II membrane protein that may be expressed as a soluble as well as full-length, cell surface-associated protein. Both surface and soluble forms of TRAIL rapidly induce apoptosis in a wide range of tumor cell lines but not normal tissue. TRAIL is expressed by activated T cells, NK cells, dendritic cells, monocytes and a variety of non-lymphoid cells. TRAIL can bind to and exert apoptosis through DR4 (TRAIL-R1) and DR5 (TRAIL-R2) receptors. It can also bind to decoy receptors, including DcR1/TRID/TRAIL-R3 and DcR2/TRUNDD/TRAIL-R4, and possibly OPG/TNFRSF11B, which may serve to regulate TRAIL activity. TRAIL has been shown to be involved in T cell-mediated cytotoxicity, but its mechanism of action remains to be fully elucidated. The RIK-2 clone was selected based on its ability to block TRAIL-mediated cytotoxic activity.
Suggested Companion Products
|Resources & Tools|
|Spectrum Viewer||Panel Designer||Spectrum Viewer||Download TDS||Regulatory Document Website|
Preparation and Storage
Store undiluted at 4°C.
This preparation contains no preservatives, thus it should be handled under aseptic conditions.
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- An isotype control should be used at the same concentration as the antibody of interest.
- Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.